AUTHOR=Lin Yubiao , Huang Kaida , Cai Zhezhen , Chen Yide , Feng Lihua , Gao Yingqin , Zheng Wenhui , Fan Xin , Qiu Guoqin , Zhuang Jianmin , Feng Shuitu 

TITLE=A Novel Exosome-Relevant Molecular Classification Uncovers Distinct Immune Escape Mechanisms and Genomic Alterations in Gastric Cancer

JOURNAL=Frontiers in Pharmacology

VOLUME=Volume 13 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.884090

DOI=10.3389/fphar.2022.884090

ISSN=1663-9812

ABSTRACT=Objective: Gastric cancer (GC) is a highly heterogeneous malignant carcinoma. This study aimed to conduct the exosome-based classification for assisting personalized therapy for GC.
Methods: Based on the expression profiling of prognostic exosome-related genes, GC patients in TCGA cohort were classified utilizing unsupervised consensus clustering approach, and the reproducibility of this classification was confirmed in the GSE84437 cohort. An exosome-based gene signature was developed via Least Absolute Shrinkage and Selection Operator (LASSO) regression analysis. Immunological features, responses to immune checkpoint inhibitors and genetic alterations were evaluated via computational methods.
Results: Two exosome-relevant phenotypes (A and B) were clustered, and this classification was independent of immune subtypes and TCGA subtypes. Exosome-relevant phenotype B had poorer prognosis and an inflamed TME relative to phenotype A. Patients with phenotype B presented higher responses to anti-CTLA4 inhibitor. Moreover, phenotype B occurred higher frequency of genetic mutation than phenotype A. The exosome-based gene signature (GPX3, RGS2, MATN3, SLC7A2 and SNCG) could independently and accurately predict GC prognosis, which was linked to stromal activation and immunosuppression.
Conclusion: Our findings offer a conceptual frame to further comprehend the roles of exosomes in immune escape mechanisms and genomic alterations of GC. More work is needed to evaluate the reference value of exosome-relevant phenotypes for designing immunotherapeutic regimens.